Tandem Diabetes Care (TNDM) EBIT Growth (5y) (2018 - 2026)
Tandem Diabetes Care (TNDM) EBIT Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.32 Bn | 174.03 Bn | 6.27 Bn |
| 2 | Stryker | 128.59 Bn | 125.71 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.77 Bn | 66.32 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.46 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.44 Bn | 26.15 Bn | 1.98 Bn |
| 7 | Dexcom | 28.41 Bn | 27.29 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.77 Bn | 26.20 Bn | - |
| 9 | Koninklijke Philips | 25.24 Bn | 22.11 Bn | 2.07 Bn |
| 10 | Tandem Diabetes Care | 1.15 Bn | 580.87 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.04% |
| Dec 31, 2025 | -14.97% |
| Sep 30, 2025 | -86.66% |
| Jun 30, 2025 | -33.90% |
| Mar 31, 2025 | -54.86% |
| Dec 31, 2024 | -17.83% |
| Sep 30, 2024 | -34.16% |
| Jun 30, 2024 | -75.19% |
| Mar 31, 2024 | -30.53% |
| Dec 31, 2023 | -130.17% |
| Sep 30, 2023 | -14.96% |
| Jun 30, 2023 | -22.62% |
| Mar 31, 2023 | -52.52% |
| Dec 31, 2022 | -13.15% |
| Sep 30, 2022 | -29.25% |
| Jun 30, 2022 | 8.39% |
| Mar 31, 2022 | 6.29% |
| Dec 31, 2021 | 24.19% |
| Sep 30, 2021 | 17.83% |
| Jun 30, 2021 | 18.32% |